AIM ImmunoTech Reschedules Investor Conference Call to January 21, 2021 at 11AM ET

Rhea-AI Summary

AIM ImmunoTech has rescheduled its investor conference call for January 21, 2021, at 11:00 a.m. ET. The call will focus on the amended AMP-511 trial treating patients with COVID-19-induced chronic fatigue symptoms, recent achievements, and future milestones. Interested parties can submit questions to management before the call. The conference will be accessible on AIM ImmunoTech's website, and a replay will be available for 90 days post-call. AIM is committed to developing therapeutics targeting various cancers, immune disorders, and viral diseases, including COVID-19.

Positive

• Rescheduled conference call provides a platform for discussing the AMP-511 trial.
• Focus on treatment developments for COVID-19-induced chronic fatigue patients.
• Potential to address recent achievements and future milestones, which could enhance investor confidence.

Negative

• None.

AIM to discuss AMP-511 trial which includes COVID-19-induced chronic fatigue “long hauler” patients and other upcoming milestones

OCALA, Fla., Jan. 15, 2021 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) today announced that it has rescheduled its investor conference call for 11:00 a.m. Eastern Time on Thursday, January 21, 2021 to discuss the recently announced commencement of the treatment of subjects with COVID-19-induced chronic fatigue-like symptoms in the amended AMP-511 trial, recent accomplishments and upcoming milestones.

Investors and other interested parties are invited to submit questions to management prior to the call's start via email to aim@crescendo-ir.com. Management respectfully requests that questions be non-compound, direct and addressing single subjects.

The conference call will be available on the Company’s website at https://aimimmuno.com/events-presentations/, or via telephone by dialing toll free 877-407-8031 for U.S. callers, or +1 201-689-8031 for international callers.

For those unable to participate at that time, a replay of the call will be archived on the Company’s website or can be accessed by dialing 877-481-4010 for U.S. callers, or +1 919-882-2331 for international callers and entering the pass code 39447. The replay will be available for 90 days.

About AIM ImmunoTech Inc.

AIM ImmunoTech Inc. is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders, and viral diseases, including COVID-19, the disease caused by the SARS-CoV-2 virus.

Contacts:

Crescendo Communications, LLC
Phone: 212-671-1021
Email: aim@crescendo-ir.com

AIM ImmunoTech Inc.
Phone: 800-778-4042
Email: IR@aimimmuno.com

FAQ

What is the purpose of the AIM ImmunoTech conference call scheduled for January 21, 2021?

The conference call aims to discuss the amended AMP-511 trial, focusing on treating COVID-19-induced chronic fatigue patients, recent accomplishments, and future milestones.

How can investors submit questions for the AIM conference call?

Investors can submit questions via email to aim@crescendo-ir.com prior to the start of the call.

Where can I listen to the AIM ImmunoTech conference call?

The conference call will be available on AIM ImmunoTech's website and can also be accessed via telephone.

What is AIM ImmunoTech's focus in therapeutic development?

AIM ImmunoTech focuses on research and development of therapeutics for various cancers, immune disorders, and viral diseases, including COVID-19.

How long will the replay of the AIM conference call be available?

The replay of the AIM conference call will be available for 90 days.